Halozyme Therapeutics (HALO) Shares Outstanding: 2009-2025
Historic Shares Outstanding for Halozyme Therapeutics (HALO) over the last 8 years, with Sep 2025 value amounting to $117.5 million.
- Halozyme Therapeutics' Shares Outstanding fell 7.60% to $117.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $117.5 million, marking a year-over-year decrease of 7.60%. This contributed to the annual value of $123.1 million for FY2024, which is 2.87% down from last year.
- Per Halozyme Therapeutics' latest filing, its Shares Outstanding stood at $117.5 million for Q3 2025, which was down 0.08% from $117.6 million recorded in Q2 2025.
- Halozyme Therapeutics' 5-year Shares Outstanding high stood at $143.4 million for Q1 2021, and its period low was $117.5 million during Q3 2025.
- Over the past 3 years, Halozyme Therapeutics' median Shares Outstanding value was $126.8 million (recorded in 2023), while the average stood at $125.9 million.
- Its Shares Outstanding has fluctuated over the past 5 years, first climbed by 5.92% in 2021, then declined by 7.60% in 2025.
- Over the past 5 years, Halozyme Therapeutics' Shares Outstanding (Quarterly) stood at $137.5 million in 2021, then dropped by 1.70% to $135.2 million in 2022, then decreased by 6.20% to $126.8 million in 2023, then dropped by 2.87% to $123.1 million in 2024, then declined by 7.60% to $117.5 million in 2025.
- Its Shares Outstanding was $117.5 million in Q3 2025, compared to $117.6 million in Q2 2025 and $123.2 million in Q1 2025.